Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform
23 mai 2018 08h00 HE
|
Spero Therapeutics, Inc.
SPR741 Phase 1b Drug-Drug Interaction Study and SPR206 IND-enabling Studies Provide Support for Further Clinical Development Phase 1b data demonstrates pharmacokinetic compatibility and...
Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update
10 mai 2018 16h05 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May
01 mai 2018 09h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases
16 avr. 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology
12 avr. 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Fourth Quarter and Full Year 2017 Operating Results and Provides Pipeline Update
02 avr. 2018 16h10 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at Upcoming Investor Conferences
22 mars 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at March Investor Conferences
01 mars 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Announces Appointment of David P. Southwell to its Board of Directors
01 févr. 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer
04 janv. 2018 07h30 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...